Invention Grant
- Patent Title: Methods of treating metabolic disorders with an FGF21 variant
- Patent Title (中): 用FGF21变体治疗代谢紊乱的方法
-
Application No.: US14630206Application Date: 2015-02-24
-
Publication No.: US09266935B2Publication Date: 2016-02-23
- Inventor: Brian R. Boettcher , Shari L. Caplan , Douglas S. Daniels , Norio Hamamatsu , Stuart Licht , Stephen Craig Weldon
- Applicant: Brian R. Boettcher , Shari L. Caplan , Douglas S. Daniels , Norio Hamamatsu , Stuart Licht , Stephen Craig Weldon
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Paul J. Paglierani
- Main IPC: A61K38/18
- IPC: A61K38/18 ; C07K14/50 ; A61K45/06 ; A61K38/00
Abstract:
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Public/Granted literature
- US20150166622A1 FUSION PROTEINS FOR TREATING METABOLIC DISORDERS Public/Granted day:2015-06-18
Information query
IPC分类:
